Llamas and alpacas in Europe: Endoparasites of the digestive tract and their pharmacotherapeutic control.
Authors: Franz Sonja, Wittek Thomas, Joachim Anja, Hinney Barbara, Dadak Agnes M
Journal: Veterinary journal (London, England : 1997)
Summary
# Editorial Summary South American camelids (SACs), particularly llamas and alpacas, face significant endoparasitic burdens across European populations, yet treatment remains challenging due to the scarcity of licensed antiparasitic drugs and limited pharmacokinetic data specific to these species. Franz and colleagues conducted a comprehensive review of digestive tract endoparasites in European camelid populations and evaluated available pharmacotherapeutic interventions based on current evidence. A critical finding was that topical pour-on formulations—commonly used in equine and ruminant practice—demonstrate extremely poor bioavailability in camelids due to the distinctive properties of their skin and hair structure, rendering them largely ineffective and necessitating alternative routes of administration. The review identifies the major gastrointestinal parasites affecting European herds and synthesises pharmacological options, though the authors emphasise the persistent knowledge gaps surrounding drug efficacy, safety margins and optimal dosing protocols in SACs. For equine professionals treating camelids or advising on their management, this work underscores the importance of avoiding off-label application of topical preparations and seeking species-specific dosing protocols through oral or parenteral routes, whilst recognising that many antiparasitic interventions in camelids remain extrapolated from cattle, sheep and goat data rather than robust SAC-specific studies.
Read the full abstract on PubMed
Practical Takeaways
- •When treating llamas and alpacas for parasites, avoid pour-on formulations and select alternative routes of administration that achieve adequate bioavailability in these species
- •Practitioners must be aware that most antiparasitic treatments are used off-label in camelids and should base dosing decisions on current literature rather than label directions for other species
- •Endoparasite control is critical for camelid health and economic viability in European operations; implement appropriate diagnostic and treatment protocols
Key Findings
- •South American camelids require off-label use of antiparasitic drugs due to lack of licensed veterinary medicinal products for this species
- •Pour-on formulations are largely ineffective in llamas and alpacas due to unique skin and hair characteristics resulting in extremely low drug bioavailability
- •Significant knowledge gaps exist regarding pharmacokinetics, safety, and efficacy of most antiparasitic drugs used in camelids
- •Endoparasitism represents a major health concern in camelids capable of causing severe clinical disease and economic losses